Nanexa NANEXA.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker NANEXA.ST. It has been listed since 17 June 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 36.1m and a net loss of SEK 11.4m. At that date it held total assets of SEK 138.1m and shareholders' equity of SEK 101.5m.

Nanexa AB engages in the development, production, and distribution of medical nanotechnology products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-17. The firm specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.

Figures and description from our data supplier, not checked against the company's own report.

• Björn Wilhelm Svanström, MBAChief Financial Officer, since 2019
• Mårten Rooth, PhDDirector, Head-R&D Atomic Layer Deposition, since 2007
• Göran Albert Torstensson Ando, MDChairman, since 2020
• Mårten Rooth, PhDDirector, Head-R&D Atomic Layer Deposition, since 2018
• Eva Nilsagård, EMBADirector
• David WestbergChief Executive Officer, since 2015
• Anders Johansson, PhDHead-Intellectual Property, since 2007
• Sten Gunnar Otto SkollingDirector, since 2019
• Urban PaulssonIndependent Director, since 2019
• Bengt Arne Gustavsson, PhD, MDIndependent Director, since 2017
• Magnus Westgren, MD, PhDIndependent Director, since 2015

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.